Publication Name	World Journal of Clinical Oncology
Manuscript ID	126778
DOI	10.5306/wjco.126778
Country	China

Category	Biochemistry & Molecular Biology
Manuscript Type	Translational Research
Article Title	Integrative multi-omics characterization of integrin alpha 11 in gastric cancer and identification of candidate therapeutic compounds
Manuscript Source	Invited Manuscript
All Author List	Pu-Yi He, Xiao-Mei Li, Long Ma, Peng Zhang and Yu-Min Li
Funding Agency and Grant Number	Funding Agency Grant Number Major Science and Technology Project of Gansu Province 20ZD7FA003 Gansu Provincial Science and Technology Program-Chief Scientist Special Project 26RCKA003
Corresponding Author	Yu-Min Li, Chief Physician, Consultant, Full Professor, PhD, Principal Investigator, Professor Emerita, Tenured Professor, Visiting Professor, Gansu Province Key Laboratory of Environmental Oncology, The Second Hospital of Lanzhou University, No.82 Cuiyingmen, Chengguan District, Lanzhou 730030, Gansu Province, China, Lanzhou 730030, Gansu Province, China. liym@lzu.edu.cn
Key Words	Gastric cancer; Integrin alpha 11; Tumor microenvironment; Drug resistance; Drug screening
Core Tip	This study systematically evaluated the clinical and biological significance of ITGA11 in gastric cancer (GC). High ITGA11 expression was associated with a poorer prognosis and was closely linked to extracellular matrix remodeling, the immune microenvironment, and resistance-associated molecular features. Structure-based virtual screening further identified Bemcentinib, LY-2090314, and Silydianin as candidate compounds with predicted binding potential toward ITGA11, thereby providing additional avenues for investigating ITGA11 as a potential biomarker and therapeutic target in GC. However, the underlying mechanisms and the ITGA11-targeting activity of these candidate compounds warrant experimental validation.
Citation	He PY, Li XM, Ma L, Zhang P, Li YM. Integrative multi-omics characterization of integrin alpha 11 in gastric cancer and identification of candidate therapeutic compounds. World J Clin Oncol 2026; In press DOI: https://doi.org/10.5306/wjco.126778
PDF	126778-in-press.pdf

Received	2026-08-13 06:35
Peer-Review Started	2026-08-21 06:22
First Decision by Editorial Office Director
Return for Revision	2026-09-03 06:34
Revised	2026-09-14 19:24
Publication Fee Transferred
Second Decision by Editor	2026-11-05 02:50
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-11-05 08:51
Articles in Press	2026-11-05 08:51
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2218-4333 (online)
Open Access	This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com